D C Smith

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint Secondary hormonal therapy
    D C Smith
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
    Semin Urol Oncol 15:3-12. 1997
  2. doi request reprint Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
    David C Smith
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 31:412-9. 2013
  3. pmc Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032
    David C Smith
    University of Michigan, Ann Arbor, Michigan 48109 5948, USA
    Urology 77:1172-6. 2011
  4. pmc Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder
    David C Smith
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Urol 180:2384-8; discussion 2388. 2008
  5. ncbi request reprint Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
    David C Smith
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Cancer 98:269-76. 2003
  6. ncbi request reprint Chemotherapy for hormone refractory prostate cancer
    D C Smith
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
    Urol Clin North Am 26:323-31. 1999
  7. ncbi request reprint Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
    D C Smith
    Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan School of Medicine, USA
    J Clin Oncol 17:1664-71. 1999
  8. ncbi request reprint Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
    D C Smith
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
    J Clin Oncol 16:1835-43. 1998
  9. ncbi request reprint Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide
    H G Munshi
    Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Cancer 91:2175-80. 2001
  10. ncbi request reprint Adjuvant and neoadjuvant therapy in prostate cancer
    C Chay
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
    Semin Oncol 28:3-12. 2001

Research Grants

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Secondary hormonal therapy
    D C Smith
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA
    Semin Urol Oncol 15:3-12. 1997
    ..In addition, it reviews hormonal agents currently in development that act by other mechanisms to inhibit prostate cancer growth...
  2. doi request reprint Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
    David C Smith
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 31:412-9. 2013
    ..We evaluated the activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort...
  3. pmc Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032
    David C Smith
    University of Michigan, Ann Arbor, Michigan 48109 5948, USA
    Urology 77:1172-6. 2011
    ..To assess the efficacy of a multiagent taxane-based chemotherapy combined with hormonal therapy in men with metastatic androgen-dependent prostate cancer in a multicenter, cooperative group, single-arm trial...
  4. pmc Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder
    David C Smith
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Urol 180:2384-8; discussion 2388. 2008
    ..This 2-arm phase II multicenter trial was designed to assess the efficacy and toxicity of neoadjuvant paclitaxel, gemcitabine and carboplatin in patients with invasive bladder cancer...
  5. ncbi request reprint Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
    David C Smith
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Cancer 98:269-76. 2003
    ..The authors conducted this clinical trial to evaluate the addition of carboplatin to the three-drug combination of paclitaxel, estramustine, and etoposide (TEE)...
  6. ncbi request reprint Chemotherapy for hormone refractory prostate cancer
    D C Smith
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
    Urol Clin North Am 26:323-31. 1999
    ..It is hoped that the enrollment of patients into properly designed clinical trials of new agents and combinations will result in the development of therapy with proven efficacy in the near future...
  7. ncbi request reprint Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
    D C Smith
    Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan School of Medicine, USA
    J Clin Oncol 17:1664-71. 1999
    ..To evaluate the combination of intravenous (IV) paclitaxel, oral estramustine, and oral etoposide in patients with advanced hormone-refractory prostate cancer...
  8. ncbi request reprint Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
    D C Smith
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
    J Clin Oncol 16:1835-43. 1998
    ..Prostate-specific antigen (PSA) has been used as a marker of advanced prostate cancer but remains controversial. To evaluate PSA as a predictor of survival, we analyzed data from sequential phase II trials of estramustine and etoposide...
  9. ncbi request reprint Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide
    H G Munshi
    Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Cancer 91:2175-80. 2001
    ..This regimen should not be considered standard therapy for the treatment of early recurrent prostate carcinoma, but further exploration of treatment in this setting is warranted...
  10. ncbi request reprint Adjuvant and neoadjuvant therapy in prostate cancer
    C Chay
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
    Semin Oncol 28:3-12. 2001
    ..While the use of chemotherapy has been limited by the lack of active agents, newer combinations have shown effectiveness in patients with hormone refractory disease, raising the possibility of their use in the adjuvant setting...
  11. ncbi request reprint Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
    B G Redman
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, Detroit, MI, USA
    J Clin Oncol 16:1844-8. 1998
    ..Both paclitaxel and carboplatin have single-agent activity against carcinoma of the urothelium. We evaluated the combination of paclitaxel and carboplatin in the treatment of advanced cancers of the urothelium...
  12. ncbi request reprint Phase II trial of suramin in patients with metastatic renal cell carcinoma
    R Dreicer
    Department of Internal Medicine, The University of Iowa, and The University of Iowa Cancer Center, Iowa City, USA
    Invest New Drugs 17:183-6. 1999
    ..The fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is well tolerated but has no activity in advanced renal cell carcinoma...
  13. ncbi request reprint Rapid ("warm") autopsy study for procurement of metastatic prostate cancer
    M A Rubin
    Department of Pathology, University of Michigan, Ann Arbor 48109, USA
    Clin Cancer Res 6:1038-45. 2000
    ..The development and expansion of this program represent a valuable resource for molecular and clinical researchers...
  14. ncbi request reprint Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer
    C J McGinn
    Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0010, USA
    J Clin Oncol 19:4202-8. 2001
    ..The primary objective of this phase I trial was to determine the maximum-tolerated dose of radiation that could be delivered to the primary tumor concurrent with full-dose gemcitabine in patients with advanced pancreatic cancer...
  15. ncbi request reprint The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminoma
    June L Chan
    Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 53:934-41. 2002
    ..The purpose of this study was to use utilities to assess the quality of life benefits associated with adjuvant RT in this setting...
  16. ncbi request reprint Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma
    Manish S Bhandari
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer 106:1715-21. 2006
    ..The current study evaluated the efficacy of oral uracil/tegafur (UFT) and leucovorin (LV) in patients with hormone-refractory metastatic prostate carcinoma...
  17. ncbi request reprint Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate
    Niklas J Mackler
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Cancer 106:2617-23. 2006
    ....
  18. ncbi request reprint The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant
    Merideth M M Wendland
    Department of Radiation Oncology, Huntsman Cancer Hospital and the University of Utah, Salt Lake City, Utah 84112, USA
    Am J Clin Oncol 30:156-62. 2007
    ..We examined the role of involved field radiation therapy (IFRT) in this setting...
  19. ncbi request reprint Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
    Maha H A Hussain
    University of Michigan, Ann Arbor, USA
    J Clin Oncol 25:2218-24. 2007
    ....
  20. ncbi request reprint Living with prostate cancer: patients' and spouses' psychosocial status and quality of life
    Laurel L Northouse
    School of Nursing and the Division of Hematology Oncology, Department of Urology, University of Michigan, Ann Arbor 48109 0482, USA
    J Clin Oncol 25:4171-7. 2007
    ..This study assessed patients' and spouses' quality of life, appraisal of illness, resources, symptoms, and risk for distress across three phases of prostate cancer: newly diagnosed, biochemical recurrence, and advanced...
  21. ncbi request reprint Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer
    N Lynn Henry
    Department of Internal Medicine, Division of Hematology, University of Michigan School of Medicine, Ann Arbor, Mich, USA
    Oncology 71:168-75. 2006
    ..In tumor models, the copper-chelating agent tetrathiomolybdate (TM) has been shown to be antiangiogenic. We evaluated the antitumor activity of TM in patients with hormone-refractory prostate cancer (HRPC)...
  22. ncbi request reprint Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma
    Niklas J Mackler
    Department of Internal Medicine, Division of Hematology Oncology University of Michigan Medical School
    Clin Genitourin Cancer 5:318-22. 2007
    ..The primary objective of this study was to assess the feasibility and efficacy of administering etoposide/estramustine/paclitaxel in hormone-sensitive metastatic prostate cancer responding to hormonal therapy...
  23. ncbi request reprint Advances in prostate cancer chemotherapy: a new era begins
    Kenneth J Pienta
    Michigan Urology Center, University of Michigan, Ann Arbor, MI, USA
    CA Cancer J Clin 55:300-18; quiz 323-5. 2005
    ..Building on these advances, several new traditional chemotherapeutic agents as well as new targeted therapies are under development...
  24. ncbi request reprint Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
    Matthew D Galsky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1439-46. 2005
    ..To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer...
  25. ncbi request reprint Randomized clinical trial of a family intervention for prostate cancer patients and their spouses
    Laurel L Northouse
    School of Nursing, University of Michigan, Ann Arbor, Michigan 48109 5482, USA
    Cancer 110:2809-18. 2007
    ....
  26. ncbi request reprint Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy
    Joseph M Herman
    Department ofRadiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Urology 64:69-73. 2004
    ..To assess, in a Phase I study, whether bladder preservation with concurrent gemcitabine and radiotherapy (RT) influenced patient-reported quality of life (QOL) as determined by the Functional Assessment of Cancer Therapy-Bladder (FACT-BL)...
  27. doi request reprint Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy
    Walter J Urba
    Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    J Urol 180:2011-7; discussion 2017-8. 2008
    ..This phase I-II study evaluated the safety, clinical activity and immunogenicity of an immunotherapy developed from human prostate cancer cell lines (PC-3 and LNCaP) modified to secrete granulocyte-macrophage colony-stimulating factor...
  28. ncbi request reprint Course of distress and quality of life in testicular cancer patients before, during, and after chemotherapy: results of a pilot study
    Peter C Trask
    Behavioral Medicine Program, University of Michigan, MI 48108, USA
    Psychooncology 12:814-20. 2003
    ..Deleterious changes in emotional distress, quality of life, and symptom distress seen in other cancer populations were not apparent in our sample of testicular cancer patients...
  29. ncbi request reprint Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma
    Beth Hellerstedt
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Cancer 98:1603-10. 2003
    ..The authors evaluated the combination of oral cyclophosphamide, oral prednisone, and diethylstilbestrol (DES) in patients with androgen-independent prostate carcinoma (AIPC)...
  30. ncbi request reprint Novel gemcitabine-containing triplets in the management of urothelial cancer
    Maha Hussain
    Division of Hematology Oncology, Wayne State University and the Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
    Semin Oncol 29:20-4. 2002
    ..The role of gemcitabine-based multiagent combinations compared with standard therapy awaits evaluation in prospectively randomized trials...
  31. ncbi request reprint Chemotherapy for localized, high-risk prostate cancer
    Samir Narayan
    Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI 48109 0010, USA
    Semin Radiat Oncol 13:152-7. 2003
    ..The role of chemotherapy in the nonmetastatic prostate, hormone-naïve prostate cancer patient will be discussed...
  32. ncbi request reprint Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer
    Maha Hussain
    Division of Hematology Oncology, Wayne State University and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
    Urology 61:774-80. 2003
    ..To evaluate the efficacy and safety of neoadjuvant docetaxel and estramustine in patients with high-risk, newly diagnosed, prostate cancer...
  33. doi request reprint Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
    Celestia S Higano
    Department of Oncology, University of Washington Seattle, Seattle, Washington, USA
    Cancer 113:975-84. 2008
    ..The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate-carcinoma cell lines modified to secrete granulocyte-macrophage-colony-stimulating factor (GM-CSF)...
  34. ncbi request reprint Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design
    Deborah A Bradley
    University of Michigan, Ann Arbor, MI 48109 0946, USA
    Clin Genitourin Cancer 5:460-3. 2007
    ..The specific hypothesis of this trial is that sunitinib will decrease progression rates in patients with advanced urothelial cancer who have obtained stable disease or better after standard chemotherapy...
  35. ncbi request reprint Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)
    Tahir Latif
    Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland OH 44195, USA
    Invest New Drugs 23:79-84. 2005
    ..Although JM-216 had moderate activity in HRPC when given on daily basis for 5 days, it is associated with significant treatment related toxicities in this patient population...
  36. ncbi request reprint Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial
    Elizabeth Kent
    Department of Internal Medicine, University of Michigan School of Medicine and Comprehensive Cancer Center, AnnArbor, 48109, USA
    J Clin Oncol 22:2540-5. 2004
    ..We conducted a phase I trial of gemcitabine given twice weekly with concurrent radiotherapy in patients with muscle-invasive bladder cancer...
  37. ncbi request reprint Combined modality treatment for prostate cancer: role of chemotherapy
    Howard M Sandler
    Department of Radiation Oncology, University of Michigan Medical School, 1500 E Medical Center Drive, UH B2C490, Ann Arbor, MI 48109 0010, USA
    Semin Oncol 30:95-100. 2003
    ..The role of chemotherapy for patients with nonmetastatic, hormone-naive prostate cancer will be discussed...
  38. ncbi request reprint Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate
    Khalid Matin
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 50:179-85. 2002
    ..Based on these data, we performed a phase I study of high-dose oral megestrol acetate and vinblastine to evaluate the safety of this regimen...
  39. ncbi request reprint Association between Agent Orange and prostate cancer: a pilot case-control study
    Veda Nargund Giri
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0946, USA
    Urology 63:757-60; discussion 760-1. 2004
    ..Prostate cancer is the most common cancer diagnosed in American men and the second leading cause of cancer deaths. An association between Agent Orange and prostate cancer has been suggested by epidemiologic studies...

Research Grants1

  1. Phase II Trial of Tetrathiomolybdate in Prostate Cancer
    David Smith; Fiscal Year: 2002
    ..The levels of these growth factors/cytokines will then be correlated with the degree of copper depletion, PSA level and response to therapy. ..